What is the appropriate dosing and administration of fenofibrate 145 mg tablets for adults requiring treatment of elevated triglycerides?

Fenofibrate 145mg Tablet Dosing and Administration

Fenofibrate 145 mg should be administered once daily without regard to meals, with mandatory renal function assessment before initiation and dose adjustment required for patients with eGFR 30-59 mL/min/1.73m² (maximum 54 mg/day), while avoiding use entirely if eGFR <30 mL/min/1.73m² 1, 2.

Standard Dosing

• Dose: 145 mg once daily
• Timing: Can be taken at any time of day, with or without food 2
• Duration: Fenofibric acid has a 20-hour half-life, supporting once-daily dosing 2

Mandatory Renal Monitoring Protocol

Before initiating fenofibrate, you must assess renal function with both serum creatinine and eGFR 1. This is critical because fenofibric acid exposure increases 2.7-fold in severe renal impairment 2.

Renal Dosing Algorithm:

• eGFR ≥60 mL/min/1.73m²: Standard dose of 145 mg daily
• eGFR 30-59 mL/min/1.73m²: Reduce dose to maximum 54 mg daily 1, 2
• eGFR <30 mL/min/1.73m²: Do not use fenofibrate 1, 2

Monitoring Schedule:

• Recheck renal function within 3 months after initiation
• Then every 6 months thereafter 1
• If eGFR drops persistently to <30 mL/min/1.73m² during treatment, discontinue fenofibrate immediately 1

Clinical Indications for Use

Fenofibrate is appropriate for:

1. Severe hypertriglyceridemia (TG ≥500 mg/dL): Primary indication to prevent pancreatitis 3, 4, 5
2. Moderate hypertriglyceridemia (TG 200-499 mg/dL): After LDL-C lowering therapy, to reduce non-HDL-C 3
3. Low HDL-C (<40 mg/dL): As adjunctive therapy after LDL-lowering treatment 3

Critical Safety Considerations

Statin Combination Therapy

If combining fenofibrate with a statin, use only low- or moderate-intensity statins 1. The combination may be considered when:

• Benefits from ASCVD risk reduction outweigh risks, OR
• Triglycerides are ≥500 mg/dL requiring additional lowering 1

Never use gemfibrozil with statins due to severe myopathy risk 1. Fenofibrate is the preferred fibrate if statin combination is needed.

Contraindications

Fenofibrate is contraindicated in:

• Severe renal impairment (eGFR <30 mL/min/1.73m²) 1, 2
• Active hepatic disease 2
• Gallbladder disease 2

Monitoring Parameters

Beyond renal function, monitor:

• Lipid panel: At 4-12 weeks after initiation, then every 3-12 months 1
• Liver enzymes: Baseline and as clinically indicated 1
• Creatine kinase: If muscle symptoms develop 1

Expected Lipid Effects

With fenofibrate 145 mg daily, expect:

• Triglyceride reduction: 30-50% 5
• HDL-C increase: 10-20% 3, 5
• LDL-C: May increase in severe hypertriglyceridemia, decrease in mild hypertriglyceridemia 5
• Non-HDL-C reduction: Significant improvement 3

Special Populations

• Elderly: No dose adjustment needed if renal function is normal 2
• Hepatic impairment: Limited data; use with caution in mild impairment, avoid in moderate-severe disease 2, 6
• Diabetes: Safe to use; may modestly improve glycemic control in patients with very high triglycerides 7, 4

Common Pitfalls to Avoid

1. Failing to check renal function before prescribing - This is the most critical error, as fenofibrate accumulates dangerously in renal impairment
2. Using full dose (145 mg) in patients with eGFR 30-59 - Must reduce to 54 mg maximum
3. Combining with gemfibrozil and statin - Use fenofibrate instead of gemfibrozil if statin combination needed
4. Not monitoring renal function during treatment - Must recheck at 3 months and every 6 months